Back

Epicyt reports positive BAFA results in Phase 1/2a gastric-bypass study

Verifying
  • Epicyt Pharma reported positive BAFA results from a Phase 1/2a study after gastric-bypass surgery.
  • The study found statistically significant reductions in urinary calcium excretion and improved calcium-homeostasis biomarkers.
  • Epicyt completed the study in March 2026 and is preparing BAFA for Phase 2b development.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.